Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Atara Biotherapeutics, Inc. (ATRA : NSDQ)

• Company Description    Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. Number of Employees: 578

• Price / Volume Information    Yesterday's Closing Price: $5.16 Daily Weekly Monthly 20 Day Moving Average: 1,131,964 shares Shares Outstanding: 93.41 (millions) Market Capitalization: $481.97 (millions) Beta: 1.92 52 Week High: $20.04 52 Week Low: $4.70 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -28.93% -22.18% 12 Week -60.88% -56.03% Year To Date -67.26% -60.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 611 GATEWAY BLVD SUITE 900 - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-278-8930 fax: - ehyllengren@atarabio.com http://www.atarabio.com

• General Corporate Information    Officers Pascal Touchon - President; Chief Executive Officer and Director Ronald Renaud - Chairman and Director Utpal Koppikar - Chief Financial Officer Roy Baynes - Director Eric L. Dobmeier - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 046513107 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 93.41 Most Recent Split Date: (:1) Beta: 1.92 Market Capitalization: $481.97 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.91 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.45 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.15 Price/Cash Flow: - Price / Sales: 20.00 EPS Growth vs. Year Ago Period: -1.16% vs. Previous Quarter: 9.37% Sales Growth vs. Year Ago Period: 105.91% vs. Previous Quarter: -3.10% ROE 03/31/22 - -122.18 12/31/21 - -103.05 09/30/21 - -87.32 ROA 03/31/22 - -78.98 12/31/21 - -71.44 09/30/21 - -64.83 Current Ratio 03/31/22 - 3.10 12/31/21 - 3.64 09/30/21 - 4.29 Quick Ratio 03/31/22 - 3.10 12/31/21 - 3.64 09/30/21 - 4.29 Operating Margin 03/31/22 - -1,451.79 12/31/21 - -1,672.28 09/30/21 - - Net Margin 03/31/22 - -1,451.79 12/31/21 - -1,672.28 09/30/21 - - Pre-Tax Margin 03/31/22 - -1,451.60 12/31/21 - -1,672.05 09/30/21 - -2,564.69 Book Value 03/31/22 - 2.40 12/31/21 - 3.16 09/30/21 - 3.51 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©